MedTrace Logo

A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer

NCT04144517 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2024-10-16

Study results available
· View outcomes & findings →

Summary

The primary objective of this study was to estimate the response rate to ALKS 4230 in combination with pembrolizumab in patients with HNSCC who had previously received anti-PD-(L)1 therapy but who had not achieved a CR.

Conditions

  • Squamous Cell Carcinoma of Head and Neck

Interventions

DRUG

Nemvaleukin Alfa

Nemvaleukin alfa IV infusion.

DRUG

Pembrolizumab

Pembrolizumab IV infusion.

Sponsors & Collaborators

  • Immune Oncology Network (ION)

    collaborator UNKNOWN

  • Mural Oncology, Inc

    lead INDUSTRY

Principal Investigators

  • Medical Director · Mural Oncology, Inc

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-05
Primary Completion
2021-10-08
Completion
2022-01-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04144517 on ClinicalTrials.gov